Performance of an automated chemiluminescence SARS-CoV-2 IG-G assay
- PMID: 32910979
- PMCID: PMC7476884
- DOI: 10.1016/j.cca.2020.09.005
Performance of an automated chemiluminescence SARS-CoV-2 IG-G assay
Abstract
Introduction: We describe our evaluation of the Abbott SARS-CoV-2 IgG assay on the Architect immunoassay analyser.
Methods: We assessed assay precision, sensitivity, specificity, positive/negative predictive values (PPV/NPV), cross-reactivity (influenza/dengue/hepatitis B and C/rheumatoid factor/anti-nuclear/double-stranded DNA/syphilis) and sample throughput in samples from real-time polymerase chain reaction (RT-PCR) positive patients/healthcare workers (HCWs)/pre-pandemic samples. We compared the cut-off indexes (COIs) between all control samples (HCWs and pre-pandemic) to generate an optimised COI limit for reactivity.
Results: The assay specificity was 99.8% (n = 980) and sensitivity was 45.9-96.7% (n = 279). When tested ≥ 14 days post-positive RT-PCR (POS), the PPV/NPV was 96.4%/99.8%. The difference between the COIs of HCWs/pre-pandemic samples was small (0.01, p < 0.0001). There was minimal cross-reactivity with other antibodies. A lower COI limit for reactivity (≥0.55, using the 99th percentile COI of our controls and ROC analysis) improved diagnostic sensitivity, especially at 0-6 days POS (45.9-55.8%), with a small decrease in specificity (98.9%). The assay throughput was 100 samples in 70 min.
Conclusion: The Abbott SARS-CoV-2 IgG assay shows excellent performance in patients ≥ 14 days POS. The difference between the COIs of HCWs and pre-pandemic samples was numerically small. A lower COI limit improves assay sensitivity with a slight decrease in specificity.
Keywords: Antibodies; Assay evaluation; Reactivity index; SARS-CoV-2.
Copyright © 2020 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
References
-
- Centers for Disease Control and Prevention, Evaluating and Testing Persons for Coronavirus Disease 2019 (COVID-19). Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html (accessed May 22, 2020).
-
- The Royal College of Pathologists of Australia, Position Statement, COVID19 IgG/IgM Rapid POCT Tests. Available at: https://www.rcpa.edu.au/getattachment/bf9c7996-6467-44e6-81f2-e2e0cd71a4... (accessed May 22, 2020).
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
